Two lines of HBV transgenic mice (derived from G7 and G26) have been produced, each of which contains a unique locus of HBV DNA and expresses 2.1-kb HBsAg transcripts preferentially in liver and kidney tissues. To investigate the regulation of HBV expression in these mice, we have examined the state of methylation and the chromatin structure in and around the HBV sequences in tissues with and without HBV gene expression. Hypomethylation of HpaII and HhaI sites in and around the HBV sequences strongly correlated with HBV gene expression, although it was clearly not sufficient for HBV expression. Alterations in chromatin configuration were detected by DNase I digestion which identified a major hypersensitive site (HS) in liver and kidney tissue. By restriction enzyme mapping and indirect end-labeling, the HS was localized to the region of the HBV enhancer in both lines of HBV transgenics. The presence of this DNase I hypersensitive site was necessary but not sufficient for HBV expression, since it was also detected in tissues not expressing HBV. An additional DNase I hypersensitive site was mapped to the core promoter region of the G7 transgene in liver and kidney tissue but not in G26 tissues. The identification of a DNase I hypersensitive site mapping to the HBV enhancer region supports the notion that this region can interact with cellular proteins and is involved in the regulation of viral gene transcription in vivo.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0042-6822(89)90190-6 | DOI Listing |
J Allergy Clin Immunol Pract
January 2025
Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Pediatric antibiotic labels are common, and unnecessary antibiotic avoidance is associated with negative personal and public health outcomes; as a result, there is an increasing emphasis on the importance of pediatric antibiotic allergy evaluations. Different testing strategies have been advised, including skin testing and challenge testing with varied doses and duration. Established consensus testing protocols are lacking.
View Article and Find Full Text PDFRev Alerg Mex
December 2024
Médica general, Facultad de Ciencias de la Salud, Universidad Militar Nueva Granada, Hospital Universitario Mayor Méderi, Colombia.
Aesthetic Plast Surg
January 2025
Primus Medical Center (GVM), Gruppo Otorinolaringoiatrico della Romagna, Via Punta di Ferro 2/c, 47122, Forlì, FC, Italy.
Background: The increasing popularity of cosmetic procedures has led to a rise in both surgical and nonsurgical interventions. Rhinoplasty, particularly nonsurgical rhinoplasty using injectable fillers such as hyaluronic acid (HA), has become highly sought after due to its minimally invasive nature. Despite its benefits, complications can occur, ranging from minor to severe.
View Article and Find Full Text PDFPhytopathology
January 2025
LSU AgCenter, 302 Life Science Building, Baton Rouge, Louisiana, United States, 70803;
and are major pests of sweetpotato. The ability of to cause symptoms and reproduce on nematode-resistant cultivars threatens the sweetpotato industry. To evaluate the penetration, development, and reproduction of and on sweetpotato, a time-course study was conducted using the genotypes 'LA14-31' (resistant to and intermediate-resistant to ), 'LA18-100' (susceptible to and resistant to ), and 'LA19-65' (resistant to and susceptible to ), with 'Beauregard' (susceptible to both species) and 'Jewel' (resistant to and intermediate-resistant to ) as controls.
View Article and Find Full Text PDFAllergy Asthma Proc
January 2025
Department of Pharmacovigilance, Pharmacovigilance and Quality Assurance Group, Torii Pharmaceutical Co., Ltd., Tokyo, Japan.
Standardized quality (SQ) house-dust mite (HDM) sublingual immunotherapy tablets (10,000 Japanese allergy units [JAU], equivalent to 6 SQ-HDM in Europe and the United States) are licensed for the treatment of HDM-induced allergic rhinitis (AR) without age restriction, based on 52-week administration clinical trials. There are no large-scale data on the administration of 10,000 JAU for > 1 year in actual clinical practice. To examine the safety and effectiveness of 10,000 JAU during use for up to 3 years at real-world clinical sites in Japan.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!